Comparison · NCT02072434-sae
Edoxaban vs Warfarin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Edoxaban vs Warfarin: serious adverse events. Trial comparisons, record NCT02072434-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02072434-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0797 | 0.0649 | 0.0975 | wilson | |
| Risk in group 2 | 0.0767 | 0.0623 | 0.0941 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00295 | -0.0199 | 0.0258 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.777 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.76 | 1.43 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Edoxaban than on Warfarin | 339 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Edoxaban | Participants randomized to receive Edoxaban | 85 | 1,067 | EG000 |
| Group 2 | Warfarin | Participants randomized to receive Warfarin | 83 | 1,082 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Treatment-emergent adverse events (TEAEs) were defined as events that started on or after the first dose of study drug or started prior to but then became worse after the first dose of study drug through 30 days after the last dose of study drug (within 2 years).
Source ClinicalTrials.gov
Trial
- Title
- Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
- NCT number
- NCT02072434
- Phases
- PHASE3
- Conditions
- Atrial Fibrillation
- Interventions
- Edoxaban, Warfarin, Enoxaparin
- Lead sponsor
- Daiichi Sankyo
- Results first posted
- 2019-03-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02072434?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02072434-sae